GlassScriptPhysician profile
Lora A Deckard-Smart
NPI 1306098884
$6,044.94
in general payments reported to CMS, 2019-2025
20 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,199 · 2022: $1,597 · 2023: $1,619 · 2024: $1,294 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,249.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,152.81 | 2022-2025 | Ingrezza |
| Abbvie INC. | $1,060.47 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $859.13 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $707.55 | 2022-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $468.58 | 2021-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $405.11 | 2022-2024 | Invega Sustenna, Spravato |
| Vanda Pharmaceuticals INC. | $307.46 | 2021-2023 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $266.30 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $246.26 | 2021-2023 | Trintellix |
| Bausch Health US, LLC | $89.21 | 2021 | |
| Lundbeck LLC | $87.51 | 2021-2022 | |
| Axsome Therapeutics, INC. | $86.33 | 2023 | Auvelity |
| Sunovion Pharmaceuticals INC. | $69.04 | 2022 | |
| Merck Sharp & Dohme LLC | $56.61 | 2021 | |
| Supernus Pharmaceuticals, INC. | $45.33 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $41.82 | 2021 | |
| Corium, LLC | $38.77 | 2024 | Azstarys |
| Avanir Pharmaceuticals, INC. | $22.03 | 2021 | |
| Tris Pharma INC | $20.66 | 2023 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $13.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lora Deckard-Smart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.